Non small cell lung cancer market

Q: Which is the leading end user segment in the market?

Hospital is the leading end user segment in the market. Read more

Non-Small Cell Lung Cancer Market, by Type (Adenocarcinoma, Squamous Cell Carcinoma, Large Cell Carcinoma, and Large Cell Neuroendocrine Tumors), by Treatment (Chemotherapy, Targeted Therapy (Bevacizumab (Avastin), Necitumumab (Portrazza), and Ramucirumab (Cyramza), Immunotherapy (Nivolumab (Opdivo), Atezolizumab (Tecentriq), and Others) , by End user ( Hospitals, Homecare, Specialty Clinics and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Request Free Sample

Feb 2020
CMI241
175 Pages
Excel & Pdf
Pharmaceutical

Summary

Non-small cell lung cancer is a group of lung cancers that behave similarly, such as squamous cell carcinoma and adenocarcinoma. Non-small cell lung cancer (NSCLC) treatment options include surgery, chemotherapy, radiation therapy, targeted therapy, and immunotherapy. Non–small cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancers.

Global non-small cell lung cancer treatment market is estimated to be valued at US$ 24,910.7 million in 2022 and is expected to exhibit a CAGR of 9.4% during the forecast period (2022-2030).

Figure 1. Global Non-small Cell Lung Cancer Treatment Market Share (%), by End User, 2022

Increasing new drug approvals for the treatment of non-small cell lung cancer are expected to drive the market growth.

Increasing new drug approvals for the treatment of non-small cell lung cancer are expected to drive the market growth. For instance, in August 2019, Roche Holding, which is a Swiss multinational healthcare company that operates worldwide under two divisions: Pharmaceuticals and Diagnostics, received the U.S. Food and Drug Administration (FDA) approval for Rozlytrek (entrectinib), which is indicated for the treatment of adults with ROS1-positive, metastatic Non-small cell lung cancer.

Figure 2. Global Non-small Cell Lung Cancer Treatment Market Share (%), by Region, 2022

Increasing prevalence of non-small cell lung cancer is expected to drive market growth during the forecast period.

Increasing prevalence of non-small cell lung cancer is expected to drive market growth during the forecast period. For instance according to data published in May 2020, by the American Lung Association, which is a voluntary health organization whose mission is to save lives by improving lung health and preventing lung disease through education, advocacy and research, stated that in 2018, an estimated 234,030 cases of lung cancer were diagnosed in the U.S.

Non-small Cell Lung Cancer Treatment Market Report Coverage

Report Coverage	Details
Base Year:	2021	Market Size in 2022:	US$ 24,910.7 Mn
Historical Data for:	2017 to 2020	Forecast Period:	2022 to 2030
Forecast Period 2022 to 2030 CAGR:	9.4%	2030 Value Projection:	US$ 50,962.7 Mn
Geographies covered:	North America: U.S. and Canada Latin America: Brazil, Argentina, Mexico, and Rest of Latin America Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific Middle East: GCC Countries, Israel, and Rest of Middle East Africa: South Africa, North Africa, and Central Africa
Segments covered:	By Type: Adenocarcinoma, Squamous Cell Carcinoma, Large Cell Carcinoma, Large Cell Neuroendocrine Tumors By Treatment: Chemotherapy, Targeted Therapy (Bevacizumab (Avastin), Necitumumab (Portrazza), Ramucirumab (Cyramza)), Immunotherapy (Nivolumab (Opdivo), Atezolizumab (Tecentriq)), Others By End User: Hospitals, Homecare, Specialty Clinics, Others
Companies covered:	Pfizer Inc., AstraZeneca plc, F. Hoffmann-La Roche Ltd., Eli Lilly and Company, Boehringer Ingelheim GMBH, Novartis AG, Bristol-Myers Squibb Company, and Merck & Co., Inc.
Growth Drivers:	Increasing new drug approvals for the treatment of non-small cell lung cancer Increasing prevalence of non-small cell lung cancer
Restraints & Challenges:	High cost of drugs used in non-small cell lung cancer treatment

Global Non-small Cell Lung Cancer Treatment Market– Impact of Coronavirus (COVID-19) Pandemic

Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization had declared it a public health emergency on January 30, 2020.

COVID-19 has affected the economy in three main ways: by directly affecting production and demand of drugs and vaccines, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to nationwide lockdowns, several countries, such as China, India, Saudi Arabia, UAE, Egypt, and others, faced problems with regard to the transportation of drugs and vaccines from one place to another.

The market for non-small cell lung cancer diagnostics was affected by restrictions on a number of screening, diagnostic, and surgical procedures at hospitals and cancer treatment facilities. However, lung cancer cases continued even throughout the pandemic, which is expected to increase demand for non-small cell lung cancer diagnostics.

Global Non-small Cell Lung Cancer Treatment Market: Key Developments

On August 23, 2021, Pfizer, which is a U.S.-based multinational pharmaceutical and biotechnology corporation acquired Trillium Therapeutics Inc., which is a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer. This acquisition strengthens Pfizer’s category leadership in Oncology with addition of next-generation, investigational immuno-therapeutics for hematological malignancies

On March 6, 2022, Bristol Myers Squibb, which is an U.S.-based multinational pharmaceutical company, acquired Turning Point Therapeutics, which is a clinical-stage precision oncology company with a pipeline of internally discovered investigational drugs designed to address key limitations of existing cancer therapies. The acquisition of Turning Point Therapeutics broadened the company’s oncology franchise by adding a best-in-class, late-stage precision oncology asset.

Global Non-small Cell Lung Cancer Treatment Market: Restraint

The high cost of drugs is a major barrier for patients to adopt these drugs easily. High cost of drugs used in non-small cell lung cancer treatment is a major factor that is expected to restrain growth of market.

Key Players

Major players operating in the global non-small cell lung cancer treatment market include Pfizer Inc., AstraZeneca plc, F. Hoffmann-La Roche Ltd., Eli Lilly and Company, Boehringer Ingelheim GMBH, Novartis AG, Bristol-Myers Squibb Company, and Merck & Co., Inc.

Table of Content

Table of Contents

*Browse 38 market data tables and 35 figures on “Global Non-small Cell Lung Cancer Treatment Market” - Global forecast to 2030

Segmentation

Detailed Segmentation:

- Frequently Asked Questions -

What is the current market size and compound annual growth rate (CAGR) of the global non-small cell lung cancer treatment market during the forecast period (2022-2030)?

Global non-small cell lung cancer treatment market size is estimated to be valued at US$ 24,910.7 million in 2022 and is expected to exhibit a CAGR of 9.4% between 2022 and 2030.

What are the major factors driving the market growth?

Factors such as increasing new drug approvals for the treatment of non-small cell lung cancer and increasing prevalence of non-small cell lung cancer are expected to drive the market growth.

Which is the leading end user segment in the market?

Hospital is the leading end user segment in the market.

What are the key factors hampering growth of the market?

The major factors hampering growth of the market include high cost of drugs used in non-small cell lung cancer treatment.

Which are the major players operating in the market?

Major players operating in the market include Pfizer Inc., AstraZeneca plc, F. Hoffmann-La Roche Ltd., Eli Lilly and Company, Boehringer Ingelheim GMBH, Novartis AG, Bristol-Myers Squibb Company, and Merck & Co., Inc.